학술논문
Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study
Document Type
article
Author
Akihiro Ohmoto; Kenji Nakano; Naoki Fukuda; Xiaofei Wang; Tetsuya Urasaki; Naomi Hayashi; Hirotaka Suto; Shohei Udagawa; Ryosuke Oki; Yasuyoshi Sato; Mayu Yunokawa; Makiko Ono; Masanori Saito; Yusuke Minami; Keiko Hayakawa; Taisuke Tanizawa; Keisuke Ae; Seiichi Matsumoto; Junichi Tomomatsu; Shunji Takahashi
Source
PLoS ONE, Vol 18, Iss 3 (2023)
Subject
Language
English
ISSN
1932-6203
Abstract
Trabectedin is a therapeutic option for patients with advanced sarcoma. While a randomized trial demonstrated its prolonged progression-free survival (PFS), the reported PFS was 1 year). The ORR in the 49 evaluable patients was 8%, and the median PFS in 51 patients was 7.5 months. Six patients (12%) achieved PFS of >1 year. Five of the six patients had metastatic lesions at trabectedin initiation. The pathological subtypes were myxoid liposarcoma (n = 2), leiomyosarcoma (n = 2), synovial sarcoma (n = 1), and Ewing sarcoma (n = 1). The final administration dose was the minimum dose (0.8 mg/m2) in two patients who continued the treatment over 20 cycles. The best radiological response was partial response (PR) in two myxoid liposarcoma patients and stable disease in four. The durations from trabectedin initiation to the first response in the two PR cases were 163 and 176 days, respectively. Our results support the validity of continuing trabectedin at a sustainable dose and interval in patients who can tolerate it. These results may be useful when considering the clinical application of trabectedin.